Innovative Report on Autoimmune Therapeutics Market with Global Innovations, Competitive Analysis, New Business Developments and Top Companies – Global Forecast to 2026

Autoimmune Therapeutics Market

The autoimmune therapeutics market was valued at USD 119,252.7 million in 2019 and is expected to grow with a CAGR of 4.2%.
Autoimmune diseases involve unusually low activity or inadequate immune system functioning, where the immune system attacks the tissues and cells of the body. Autoimmune diseases reduce the ability of the body to combat foreign agents, causing infectious disease vulnerability. The condition is more prevalent in women than men, and in the U.S. it is also a significant cause of morbidity. As per the National Institute of Health, in the U.S., autoimmune disease affects around 50 million people. Some examples of autoimmune diseases include Crohn's disease, rheumatoid arthritis, inflammatory bowel disorder, multiple sclerosis, and systemic lupus erythematosus.
Asia-Pacific is projected to exhibit lucrative growth in the autoimmune therapeutics market on account of rapidly improving health services, rising patient awareness of early treatment of autoimmune diseases, favorable regulatory policies for newer therapeutics, such as biosimilar. For instance, in January 2018, Glenmark Pharmaceuticals launched biosimilar for Humira in the Indian market. The introduction of a new biosimilar in the near future is projected to create a significant shift in prescription patterns for autoimmune therapeutics.

As per the National Stem Cell Foundation, autoimmune diseases affect about 4% of the world’s population and comprise over 80 different disease conditions. As per the U.S. National Library for Medicines and National Institute of Health, about 3.3 million patients received pharmacological treatment for autoimmune diseases, with an average cost of therapy being USD 12,545 per year. The estimated annual therapy cost for autoimmune therapy continues to increase at a higher rate during the forecast period and is predicted to hit an approximate value of USD 13,400 by 2023.  

Technological advancements and increasing diagnostic laboratory automation are bolstering the adoption rate of autoimmune disease diagnosis. Clinicians are adopting advanced technology to conduct multiple tests at the same time with faster and precise diagnostic results. Slow turnaround time associated with the usage of conventional disease diagnostic techniques and the presence of fewer standardized tests, for more than 80 autoimmune disease types, are compelling the laboratories to shift towards automation of diagnostic laboratories.

The governments and organizations, such as the Autoimmunity Centers of Excellence, Cooperative Study Group for Autoimmune Disease Prevention, and North American Rheumatoid Arthritis Consortium, are continuously working to raise awareness regarding proper diagnosis and treatment of autoimmune diseases. A survey conducted in 2015 by the American Autoimmune Related Diseases Association, Inc. (AARDA) indicates that an American patient's ability to detect an autoimmune disorder has improved by 10%. The disease-modifying anti-rheumatic drugs (DMARDS), on the other hand, are now used as the gold standard for mild to severe rheumatoid arthritis treatment. Biologic drugs are more effective in the treatment of rheumatoid arthritis and other autoimmune diseases. In contrast, traditional DMARDs and NSAIDs merely offer symptomatic relief, further driving the demand for biologics in autoimmune therapeutic.

The rheumatic disease segment held the highest market share in 2017 and is expected to dominate the market during the forecast period on account of the surging prevalence of arthritis and the wide availability of advanced therapeutics for the treatment of rheumatic disease.  As per the Arthritis Foundation, in the U.S., around 64% of the population within the age group of 65 suffers from rheumatoid arthritis. Apart from this, increasing awareness regarding disease therapies and rising healthcare expenditure in developed regions drives the segment growth. The online pharmacy segment is projected to witness considerable growth on account of shifting consumer preference towards online drug purchasing. Apart from this, increasing awareness about online pharmacy and rising number of internet users drives the segment growth. The retail pharmacies segment, on the other hand, is projected to dominate the market on account of the presence of hospitals and clinics adopting autoimmune therapies.

Obtain Brochure For Latest Technology Advancements @ 
https://straitsresearch.com/report/autoimmune-therapeutics-market/request-sample

The Major Prominent Players Covered in this Report:
AbbVie, Amgen, Novartis, Eli Lilly and Company., Pfizer, Hoffmann-La Roche AG, Astrazeneca Plc and Bristol-Myers Squibb Co., Abbott Laboratories, Genentech Inc., Merck & Co. Inc., Bayer Schering Pharma AG., Biogen Idec Inc., GlaxoSmithKline Plc, Elan Corporation Plc, Chugai Pharmaceutical Co. Ltd. & More.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Autoimmune Therapeutics Market: Segmentation-
By Drug class- NSAIDs, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Monoclonal Antibodies,
By Disease type- Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, Type 1 Diabetes,
By Distribution Channel- Hospitals and Clinics, Retail Pharmacies, Online Pharmacies

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of Steerable Medical Devices in these regions, from 2019 to 2026, covering:
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

View this report with a detailed description and TOC @ 
https://straitsresearch.com/report/autoimmune-therapeutics-market/toc

Impact of COVID-19 -
The ongoing COVID-19 pandemic has compelled the market players to radically rethink their strategies and the way they operate their businesses. The impact of COVID-19 can be traced in shortage of supply and decline in production of drug products owing to shifting focus of market players on therapeutics for novel coronavirus. The patients receiving autoimmune drug therapy are prone to SARS-CoV-2 infections; however, the suspension of ongoing therapy is contraindicated to prevent flares of disease, and the consequent increase in the risk of infection. The autoimmune therapeutics market is currently facing shortfall due to the COVID-19; however, the market is projected to gain momentum post-COVID-19.

Key Autoimmune Therapeutics Market Trends:
- The report identifies, determines, and forecasts the Global Autoimmune Therapeutics Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
- Industry to Industry Holds Largest Share in the Autoimmune Therapeutics Market
- It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
- Demand from Regional / geographical is Expected to Drive the Growth
- Rising Adoption of Market Segments in this Growth
- North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
- It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Autoimmune Therapeutics Market.

Recent Developments -
On July 23, 2019, the U.S.FDA approved a biosimilar drug developed by Pfizer, Ruxience (rituximab-over), for certain cancers and autoimmune disorders

In December 2019, GSK announced positive results for phase III clinical studies of Benlysta (belimumab) indicated for systemic lupus erythematosus (SLE), an autoimmune disorder attacking healthy tissues

Key Questions Answered in The Report:
What will the Autoimmune Therapeutics market growth rate be?
What are the key factors driving the global Autoimmune Therapeutics market?
Who are the key manufacturers in the Autoimmune Therapeutics market space?
What are the market opportunities, market risk, and market overview of the Autoimmune Therapeutics market?
What are sales, revenue, and price analysis of top manufacturers of the Autoimmune Therapeutics market?
Who are the distributors, traders, and dealers of the Autoimmune Therapeutics market?
What are the market opportunities and threats faced by the vendors in the global Steerable Medical Devices Industry?
What are sales, revenue, and price analysis by types and applications of the Autoimmune Therapeutics Industry?
What are sales, revenue, and price analysis by regions of Autoimmune Therapeutics industry?
What are the driving factors contributing to market growth during the short, medium, and long term?

Browse Full Report @ 
https://straitsresearch.com/report/autoimmune-therapeutics-market/

Even if your business is a multinational venture or a single storefront, we believe innovation is the key to progress, in both what you build and how you promote your products and brands.

Buy Full Report with Detail Analysis with COVID-19 Impact – https://straitsresearch.com/buy-now/autoimmune-therapeutics-market/global/

So let's put our minds together. We'll make your vision a reality and help you grow.

For more details, please contact us -
Straits Research
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY 10022
Tel: +1 646 480 7505, +44 208 068 9665
Website: https://straitsresearch.com/

About Us:
Regardless of whether you're looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with what customers purchase. We overcome the issues of our customers by recognizing and deciphering just the target group, while simultaneously generating leads with the highest precision. We seek to collaborate with our customers to deliver a broad spectrum of results through a blend of market and business research approaches. This approach of using various research and analysis strategies enables us to determine greater insights by eliminating the research costs.

This release was published on openPR.